Stockscreener 앱 받기
0.8452
1.86%
-0.016
전일 마감가:
$0.8612
열려 있는:
$0.861
하루 거래량:
291.42K
Relative Volume:
1.34
시가총액:
$31.93M
수익:
$22.33M
순이익/손실:
$-85.89M
주가수익비율:
-0.3684
EPS:
-2.2942
순현금흐름:
$-89.47M
1주 성능:
-14.90%
1개월 성능:
-27.14%
6개월 성능:
-41.31%
1년 성능:
-73.00%
1일 변동 폭
$0.835
$0.8799
1주일 범위
$0.835
$1.06
52주 변동 폭
$0.835
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
명칭
Metagenomi Therapeutics Inc
전화
(510) 871-4880
주소
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
0.8452 | 31.93M | 22.33M | -85.89M | -89.47M | -2.2942 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-07 | 재개 | Chardan Capital Markets | Buy |
| 2024-05-07 | 개시 | H.C. Wainwright | Buy |
| 2024-05-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-03-05 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-05 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2024-03-05 | 개시 | Jefferies | Buy |
| 2024-03-05 | 개시 | TD Cowen | Outperform |
| 2024-03-05 | 개시 | Wells Fargo | Overweight |
모두보기
Metagenomi Therapeutics Inc 주식(MGX)의 최신 뉴스
Metagenomi Therapeutics Submits September 2026 Corporate Presentation to SEC Under Regulation FD - Kalkine Media
TScan Therapeutics (Nasdaq:TCRX)Stock Analysis - simplywall.st
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com South Africa
Metagenomi director Laurence Reid buys $23,401 in company stock - Investing.com
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com Canada
Metagenomi director Laurence Reid buys $23,401 in company stock By Investing.com - Investing.com Australia
Metagenomi director Laurence Reid buys $23,401 in company stock - Investing.com
Director buys 20,000 Metagenomi Therapeutics (MGX) shares in open-market deal - stocktitan.net
Metagenomi (MGX) counsel’s tax sale covers RSU vesting - stocktitan.net
Automatic tax sale trims Metagenomi (MGX) CEO stake - stocktitan.net
Metagenomi general counsel Matthew Wein sells $414 in stock - Investing.com
Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock - Investing.com
A 7.3% slice of Metagenomi Therapeutics (MGX) is held by one investor - Stock Titan
Metagenomi CFO Pamela Wapnick sells $2,213 in tax-related stock By Investing.com - Investing.com UK
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - Barchart.com
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - manilatimes.net
Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Price, MGX Stock News, MGX Share Price & Updates - Kalkine
Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Price, MGX Stock News, MGX Share Price & Updates - kalkine.ca
MGX Q2 2026 Earnings: Wider-than-Expected Loss Highlights Gene Editing Cash BurnRevenue Per Share - careplusvn.com
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Metagenomi Therapeutics (NasdaqGS:MGX) Stock Forecast & Analyst Predictions - Simply Wall Street
Metagenomi Therapeutics (MGX) Holds Flat at $1.23 as Gene-Editing Stock Consolidates Between Support and ResistanceAAII Bullish - careplusvn.com
Metagenomi Therapeutics (MGX) Holds Flat at $1.23 as Gene-Editing Stock Consolidates Between Support and ResistanceOversold Bounce Ideas - dars.gov.et
Metagenomi Therapeutics (MGX) Holds Steady at $1.23 as Biotech Consolidates Between Key LevelsBreakout Stock Alerts - vinanet.vn
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - webull.com
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - kens5.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - Yahoo Finance
Metagenomi Therapeutics 2Q 2026: Revenue $(0.3)M, EPS $(0.73) — 10-Q Summary - TradingView
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Metagenomi Therapeutics (MGX) Edges Lower to $1.23 as Gene-Editing Stock Tests Key Technical RangeUnusual Put Volume - careplusvn.com
MGX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesQuarterly Earnings - vinanet.vn
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesVolume Dry Up - careplusvn.com
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesMarket Neutral Pair - dars.gov.et
Amazon has Q2 sales of $200bn - Electronics Weekly
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineManagement Tone Analysis - vinanet.vn
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineAnnual Financial Report - dars.gov.et
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineSaaS Earnings Trends - dars.gov.et
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineEPS Growth Rate - dars.gov.et
Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX - TradingView
Metagenomi Therapeutics Inc (MGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Metagenomi Therapeutics Inc 주식 (MGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wein Matthew | See Remarks |
Sep 08 '26 |
Sale |
1.16 |
358 |
415 |
126,133 |
| Wapnick Pamela | Chief Financial Officer |
Sep 08 '26 |
Sale |
1.16 |
1,911 |
2,214 |
206,580 |
| Irish Jian | See Remarks |
Sep 08 '26 |
Sale |
1.16 |
2,140 |
2,479 |
375,393 |
| Wein Matthew | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
558 |
725 |
126,491 |
| Wapnick Pamela | Chief Financial Officer |
Jun 05 '26 |
Sale |
1.30 |
2,884 |
3,746 |
208,491 |
| Irish Jian | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
3,737 |
4,854 |
377,533 |
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '26 |
Sale |
1.60 |
1,581 |
2,530 |
187,375 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
1.35%
자본화:
|
볼륨(24시간):